Artikel
Antibodies against MYC-associated Zinc Finger Protein: An Independent Marker in Acute Coronary Syndrome?
Suche in Medline nach
Autoren
Veröffentlicht: | 4. September 2017 |
---|
Gliederung
Text
Background: Atherosclerosis is considered the pathophysiology underlying cardiovascular (CVD), cerebrovascular and peripheral vascular diseases. Increasing evidence supports autoimmunity in atherosclerosis. Imaging studies have correlated MYC-associated zinc finger protein antibodies (MAZ-Ab) with atherosclerotic plaque activity. This study examines the prevalence of MAZ-Ab in patients presenting with acute coronary syndrome versus healthy controls, and their relationship to traditional cardiovascular risk factors.
Methods: Clinical data on patients admitted with proven acute coronary syndrome (ACS) between August 2007 and September 2008 was collected. Serum samples, taken at presentation were retrospectively tested for MAZ-Ab. Further serum from healthy volunteers, proven to have no CVD risk factors acted as controls.
Results: Serum MAZ-Ab was evaluated in 270 individuals, with 174/270 patients (64%) having had an ACS. Among these patients, median MAZ-Ab optical density was significantly higher compared to controls (0.27 vs. 0.46; P=0.001). While the majority of patients (116/174; 67%) in the ACS group had suffered from a ST elevation myocardial infarction, there was no significant difference in MAZ-Ab between the various ACS sub-types (P=0.682). No relationship between MAZ-Ab titre and conventional cardiovascular risk factors could be identified.
Conclusion: Patients presenting with any type of ACS demonstrated significantly higher MAZ-Ab titres than known healthy controls. Given current knowledge of MAZ-Ab function, these findings support an autoimmune component to CVD. This effect may be independent of conventional risk factors. Additionally MAZ-Ab titre appears unrelated to the extent of end-organ damage. Further research is needed to evaluate the prognostic value of MAZ-Ab as an additional risk factor for CVD.